In This Article:
Over the last 7 days, the United States market has dropped 4.4%, yet it remains up by 7.5% over the past year, with earnings projected to grow by 14% annually. In this context of fluctuating performance and optimistic earnings forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to changing market dynamics.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 26.18% | 36.69% | ★★★★★★ |
| Alkami Technology | 21.98% | 85.17% | ★★★★★★ |
| Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
| AVITA Medical | 27.78% | 55.33% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.82% | 58.64% | ★★★★★★ |
| Blueprint Medicines | 22.38% | 55.75% | ★★★★★★ |
| Applied Optoelectronics | 58.93% | 141.15% | ★★★★★★ |
| TKO Group Holdings | 21.90% | 25.17% | ★★★★★★ |
| Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
Click here to see the full list of 242 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Rezolve AI
Simply Wall St Growth Rating: ★★★★★☆
Overview: Rezolve AI Limited offers artificial intelligence solutions for the commerce sector and has a market capitalization of $332.05 million.
Operations: Rezolve AI Limited generates revenue primarily from its Internet Software & Services segment, amounting to $0.15 million.
Rezolve AI, with a forecasted annual revenue growth of 45%, is outpacing the U.S. market average of 8.4%, signaling robust potential in high-growth tech sectors. Despite its current unprofitability and shareholder dilution over the past year, the company's strategic initiatives, including a $1 billion Bitcoin treasury to support its upcoming AI-driven crypto payment platform, highlight its innovative approach to integrating AI and blockchain technologies. This bold move not only secures Rezolve AI's financial position but also aligns it with future digital economy trends, potentially revolutionizing global commerce through enhanced payment solutions and cryptocurrency integration.
Blueprint Medicines
Simply Wall St Growth Rating: ★★★★★★
Overview: Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, with a market cap of $5.61 billion.
Operations: The company generates revenue from its pharmaceuticals segment, totaling $508.82 million.
Blueprint Medicines, amid a challenging landscape for biotech innovation, is making notable strides with a forecasted annual revenue growth of 22.4%, outpacing the U.S. market average of 8.3%. Despite being currently unprofitable, the company's robust pipeline and recent positive trial results for AYVAKIT® suggest potential future profitability, underscored by an impressive projected return on equity of 48.3% in three years' time. The firm's strategic focus on mast cell-driven diseases and advanced systemic mastocytosis treatments was highlighted at the recent AAAAI/WAO Joint Congress, demonstrating its commitment to addressing unmet medical needs through high-potential R&D investments totaling $508 million last year—a significant figure that underscores its dedication to innovation in biotechnology.